A Pediatric Phase 1 Trial Of Vorinostat And Temozolomide In Relapsed Or Refractory Primary Brain Or Spinal Cord Tumors: A Children’s Oncology Group Phase 1 Consortium Study

PURPOSE: We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hummel, Trent R., Wagner, Lars, Ahern, Charlotte, Fouladi, Maryam, Reid, Joel M., McGovern, Renee M., Ames, Matthew M., Gilbertson, Richard J., Horton, Terzah, Ingle, Ashish M., Weigel, Brenda, Blaney, Susan M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4139006/
https://ncbi.nlm.nih.gov/pubmed/23554030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24541
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi